Clinical Trials Browser

Phase 2 × camrelizumab × Tumor-Agnostic × Clear all

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 2 Active not recruiting

Adenocarcinoma